CytomX Therapeutics, Inc. (CTMX)
NASDAQ: CTMX · IEX Real-Time Price · USD
1.380
+0.020 (1.47%)
At close: Jul 19, 2024, 4:00 PM
1.390
+0.010 (0.72%)
Pre-market: Jul 22, 2024, 7:01 AM EDT
CytomX Therapeutics Revenue
CytomX Therapeutics had revenue of $119.18M in the twelve months ending March 31, 2024, with 76.24% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $41.46M with 76.45% year-over-year growth. In the year 2023, CytomX Therapeutics had annual revenue of $101.21M with 90.38% growth.
Revenue (ttm)
$119.18M
Revenue Growth
+76.24%
P/S Ratio
0.90
Revenue / Employee
$976,869
Employees
122
Market Cap
107.53M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 101.21M | 48.05M | 90.38% |
Dec 31, 2022 | 53.16M | 15.85M | 42.48% |
Dec 31, 2021 | 37.31M | -31.12M | -45.47% |
Dec 31, 2020 | 68.43M | 41.53M | 154.36% |
Dec 31, 2019 | 26.90M | -32.60M | -54.79% |
Dec 31, 2018 | 59.50M | -12.12M | -16.92% |
Dec 31, 2017 | 71.62M | 56.58M | 376.12% |
Dec 31, 2016 | 15.04M | 7.33M | 95.06% |
Dec 31, 2015 | 7.71M | 2.64M | 51.90% |
Dec 31, 2014 | 5.08M | 4.19M | 471.73% |
Dec 31, 2013 | 888.00K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
FibroGen | 167.49M |
InterCure | 97.95M |
Journey Medical | 80.00M |
BrainsWay | 34.26M |
Elutia | 28.99M |
Armata Pharmaceuticals | 4.70M |
Zentek | 21.92K |
CTMX News
- 4 weeks ago - CytomX Therapeutics to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference - GlobeNewsWire
- 4 weeks ago - CytomX Therapeutics Promotes Chris Ogden to Chief Financial Officer - GlobeNewsWire
- 2 months ago - CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference - GlobeNewsWire
- 2 months ago - CytomX Therapeutics Announces New Employment Inducement Grants - GlobeNewsWire
- 2 months ago - CytomX stock down 30% despite encouraging cancer study results - Invezz
- 2 months ago - CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 2 months ago - CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 (EGFRxCD3 PROBODY® T-Cell Engager) - GlobeNewsWire
- 2 months ago - CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination with KEYTRUDA® (pembrolizumab) - GlobeNewsWire